We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Cancer Liquid Biopsy Assay Detects Low-Level Mutations

By LabMedica International staff writers
Posted on 08 Oct 2018
Circulating free DNA sequencing (cfDNA-Seq) can portray cancer genome landscapes, but highly sensitive and specific technologies are necessary to accurately detect mutations with variant frequencies that are often low.

A cell-free DNA assay has been developed to detect low-frequency mutations in colorectal cancer. More...
The assay initially is to be used for translational studies but a clinical version of the test is under development that might also be applicable to lung and other cancers.

An international team of scientists working with the Institute of Cancer Research (London, UK) has developed a customizable hybrid-capture cfDNA-Seq technology using off-the-shelf molecular barcodes and a novel duplex DNA molecule identification tool for enhanced error correction. The team designed a 32-gene assay, 163.3-kilobase pairs in size, using Agilent SureSelectXT HS technology to which they had early access. The reagent kit incorporates 10-base molecular barcodes. To calculate the sensitivity and specificity of the assay, the team created a mixture of cfDNA with 16 known single nucleotide polymorphisms (SNPs) within the targeted region at various concentrations.

The group then tested the assay on cfDNA from 28 patients with metastatic colorectal cancer who also had a tumor biopsy sequenced. The cfDNA assay detected 80/91 (88%), of the mutations that had been found by tumor sequencing. The cfDNA sequencing assay also detected mutations in genes that had not previously been analyzed by tumor sequencing. For instance, in four cases that had previously been analyzed via a 5-gene amplicon-based assay, the cfDNA assay detected mutations in the APC gene, a well-known tumor suppressor gene. In addition, the cfDNA assay detected mutations in the FBXW7, CTNNB1, TCF7L2, ATM, and SMAD4 genes. Eleven out of 13 mutations detected resulted in protein changes and that had been reported in the COSMIC database.

Marco Gerlinger, MD, a clinical scientist and senior author of the study, said, “We're interested in discovering resistance mechanisms and new drivers of metastatic disease, so we needed the option of changing around what we want to include in our sequencing assay. While commercially available assays that make use of amplicon technology are customizable, the team also wanted the ability to look at genome-wide copy number alterations, which can be more challenging with amplicon-based assays than with hybrid capture-based ones.” The study was published in the October 2018 issue of the journal Clinical Chemistry.

Related Links:
Institute of Cancer Research


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
Staining Management Software
DakoLink
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.